NT 501

Drug Profile

NT 501

Alternative Names: Ciliary neurotrophic factor - Neurotech; Ciliary neurotrophic factor implant - Neurotech; CNTF implant - Neurotech; Encapsulated CNTF - Neurotech; NT-501; Retinitis pigmentosa encapsulated cell therapy - Neurotech; Rexenus

Latest Information Update: 30 Nov 2016

Price : $50

At a glance

  • Originator Neurotech USA
  • Developer National Eye Institute; Neurotech USA; Stanford University; University of Miami
  • Class Cell therapies; Eye disorder therapies
  • Mechanism of Action Ciliary neurotrophic factor replacements; Neurogenesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Retinal telangiectasis; Retinitis pigmentosa
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Dry macular degeneration; Retinitis pigmentosa
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Retinitis pigmentosa
  • Phase II Glaucoma; Retinal telangiectasis; Usher syndromes
  • Phase I/II Colour vision defects
  • Phase I Optic nerve disorders
  • No development reported Dry macular degeneration

Most Recent Events

  • 01 Sep 2016 Neurotech completes a phase I trial for Retinal telangiectasis in USA (NCT01327911)
  • 01 Jun 2016 Phase-II clinical trials in Glaucoma in USA (Intravitreous) (NCT02862938)
  • 22 Jun 2015 NT 501 is still in phase II/III development for Retinitis pigmentosa in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top